Lancet[journal] 检索结果

241. Extended aromatase inhibitor therapy for early breast cancer.

作者: A Sathiya Susuman.;Tlaleho Ramangoele.;Ludwe Petros.;Khanyo Dhludhlu.;Siyasanga Hitilana.;Thela Nonkonyane.
来源: Lancet. 2026年407卷10527期495页

242. Extended aromatase inhibitor therapy for early breast cancer - Authors' reply.

作者: Jeremy Braybrooke.;Rosie Bradley.;Robert Hills.; .
来源: Lancet. 2026年407卷10527期495-496页

243. Extended aromatase inhibitor therapy for early breast cancer.

作者: Arunkumar Krishnan.;Diptasree Mukherjee.
来源: Lancet. 2026年407卷10527期494-495页

244. Universal health coverage, Knowledge Hub, and debt-to-health.

作者: Ryuichi Komatsu.;Colleen Daniels.;Rachel Ong.;Gorik Ooms.;Magda Robalo.
来源: Lancet. 2026年407卷10527期493页

245. Universal health coverage in sub-Saharan African: elegant on paper.

作者: Josephine Aikpitanyi.
来源: Lancet. 2026年407卷10527期493-494页

246. Civil society and faith-based responses to drone warfare.

作者: Raman Bedi.;Santiago Gallardo Pezet.
来源: Lancet. 2026年407卷10527期492-493页

247. Cancer medicines remain absent from global access metrics.

作者: Kristina Jenei.;Richard Sullivan.
来源: Lancet. 2026年407卷10527期491-492页

248. Deciding with, not for.

作者: Rafal Zadykowicz.
来源: Lancet. 2026年407卷10527期486-487页

249. Abraham Verghese: the body as text.

作者: Faith McLellan.
来源: Lancet. 2026年407卷10527期484页

250. Offline: India-taking the pulse of a nation.

作者: Richard Horton.
来源: Lancet. 2026年407卷10527期479页

251. Winner of the 2025 Wakley-Wu Lien Teh Prize: beyond precision medicine.

作者: Esther Lau.;Helena Hui Wang.;Yuanyuan Wang.;Shangrong Han.;Jiefang Huang.;Pingyue Jin.;Haoyu Wang.;Peng Zhang.;Baoguo Jiang.;Richard Horton.
来源: Lancet. 2026年407卷10527期477-478页

252. Cancer and acute coronary syndrome: from risk assessment to personalised clinical decision making.

作者: Jennifer E Liu.;Dmitriy N Feldman.
来源: Lancet. 2026年407卷10527期474-475页

253. AI for enhancing efficiency and effectiveness of population breast cancer screening.

作者: M Luke Marinovich.;Nehmat Houssami.
来源: Lancet. 2026年407卷10527期471-473页

254. Resident doctors: an investment in the future of the NHS.

作者: The Lancet.
来源: Lancet. 2026年407卷10527期469页

255. Triple cardiovascular disease detection with an artificial intelligence-enabled stethoscope (TRICORDER) in the UK: a cluster-randomised controlled implementation trial.

作者: Mihir A Kelshiker.;Patrik Bächtiger.;Camille F Petri.;Saloni Nakhare.;Josephine Mansell.;Karanjot Chhatwal.;Abdullah Alrumayh.;Jahed Zaman.;Moulesh Shah.;Holly Young.;Helena Roy.;Melanie T Almonte.;Céire Costelloe.;Yasmin Razak.;Azeem Majeed.;James P Howard.;Carys Barton.;Daniel B Kramer.;Carla M Plymen.;Nicholas S Peters.
来源: Lancet. 2026年407卷10529期704-715页

Early detection of cardiovascular disease is a global public health priority. Artificial intelligence (AI)-enabled stethoscopes offer robust performance characteristics in point-of-care detection of heart failure, atrial fibrillation, and valvular heart disease (VHD). We conducted a pragmatic, cluster-randomised controlled implementation trial to determine the real-world effect and implementation challenges of AI-stethoscopes.

256. Implementation first: lessons from the TRICORDER trial in UK primary care.

作者: Sergio Cinza-Sanjurjo.;Jose R González-Juanatey.
来源: Lancet. 2026年407卷10529期653-654页

257. TRPC6 inhibition: podocyte-targeted treatment for focal segmental glomerulosclerosis?

作者: Marina Vivarelli.;Priya S Verghese.
来源: Lancet. 2026年407卷10528期549-551页

258. TRPC6 inhibition for the treatment of focal segmental glomerulosclerosis: a randomised, placebo-controlled, phase 2 trial of BI 764198.

作者: Howard Trachtman.;Matthias Kretzler.;Loreto Gesualdo.;Nicholas Cross.;Biruh Workeneh.;Jessica Kaufeld.;Björn Meijers.;Zhiming Ye.;Qinkai Chen.;Vimal K Derebail.;Monica Suet Ying Ng.;Bo Ji.;Maximilian T Lobmeyer.;Silke Retlich.;Fabia T Licarião Rocha.;Srinivasa Prasad.;Nima Soleymanlou.
来源: Lancet. 2026年407卷10528期587-598页

In focal segmental glomerulosclerosis (FSGS), transient receptor potential cation channel, subfamily C, member 6 (TRPC6) overactivity might cause podocyte loss and progressive kidney function decline. This exploratory study assessed the safety and efficacy of a novel once-daily oral selective TRPC6 inhibitor, BI 764198.

259. BCMA-CD3 T-cell engager as salvage therapy for multirefractory primary immune thrombocytopenia.

作者: Jesus Duque-Afonso.;Christoph Rummelt.;Katharina Förster.;Robert Zeiser.;Dimitrios Mougiakakos.
来源: Lancet. 2026年407卷10527期489-491页

260. The NHS 10-year plan: between aspiration and implementation.

作者: Michael Anderson.;Emma Pitchforth.;Alistair McGuire.;Elias Mossialos.
来源: Lancet. 2026年407卷10529期728-732页

结果排序

文献格式

出版时间

出版类型

出版语言